Foundations Of Immuno-Oncology: Advancing Basic Science & Translational Research

The field of immuno-oncology (I-O), aimed at developing novel strategies for therapeutic intervention, represents an especially dynamic area of cancer research. Immuno-oncology has progressed tremendously and today immunotherapy is one of the most promising approaches in the fight against various cancer types.

Rituximab in particular has experience great progress, with several immunotherapies developed and clinically tested since it launch over two decades ago. Monoclonal antibodies, checkpoint inhibitors, small molecules, cytokines, adoptive cell transfers, and other cell-based therapies have all made their way into the clinic. The increasing pace of discovery and development is continuing to amplify, the need for sensitive tools, accurate methods, and efficient technologies. Nonetheless, success in this research area can be impeded by deep-rooted and intertwined cellular interactions, signaling pathways, mechanisms of tumor immune evasion, and the potentially grave adverse responses observed with immunotherapy. Moreover, these factors are further compounded by often sparingly available, time-sensitive, and highly heterogeneous samples from which meaningful conclusions are demanded. Such challenges are inherent to the biology of the field, but they should not be further complicated by the technical approach you choose.

Bio-Techne unites the world-class brands of R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, and Advanced Cell Diagnostics, Inc., to uncomplicate your workflow and better support the I-O research community. Investigate immunotherapeutic approaches that are at the forefront of the field for targeting solid tumor types and their associated challenges, and learn more about our diverse portfolio of solutions and capabilities that help researchers advance their discoveries to the clinic.